Vineet Laboratories Limited Total Liabilities

Latest as of September 2025: Rs764.24 Million INR ≈ $8.26 Million USD

Vineet Laboratories Limited total liabilities. Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has total liabilities worth Rs764.24 Million INR (≈ $8.26 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VINEETLAB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Vineet Laboratories Limited (2017–2025)

Total liabilities of Vineet Laboratories Limited from 2017 to 2025. This chart illustrates how Vineet Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data.

Vineet Laboratories Limited Competitors by Total Liabilities

The table below lists competitors of Vineet Laboratories Limited ranked by their total liabilities.

Company Country Total Liabilities
Infimer Ltd
TA:INFR
Israel ILA7.50 Million
Weha Transportasi Indonesia TBK
JK:WEHA
Indonesia Rp137.49 Billion
Fatfish Group Ltd
AU:FFG
Australia AU$12.26 Million
Imperial Pacific Ltd
AU:IPC
Australia AU$1.81 Million
Conduit Holdings Ltd
LSE:CRE
UK GBX1.36 Billion
THG Holdings PLC
LSE:THG
UK GBX1.11 Billion
Minrex Resources Ltd
AU:MRR
Australia AU$178.64K
Radiant Utama Interinsco Tbk
JK:RUIS
Indonesia Rp711.69 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Vineet Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Vineet Laboratories Limited's balance sheet.

Liquidity & Leverage Metrics

Vineet Laboratories Limited Total Liabilities Ratios Explained

Vineet Laboratories Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 5.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.84 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vineet Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vineet Laboratories Limited (2017–2025)

The table below shows the annual total liabilities of Vineet Laboratories Limited from 2017 to 2025.

Year Total Liabilities Change
2025-03-31 Rs798.92 Million
≈ $8.64 Million
-2.75%
2024-03-31 Rs821.48 Million
≈ $8.88 Million
-0.02%
2023-03-31 Rs821.66 Million
≈ $8.89 Million
-18.17%
2022-03-31 Rs1.00 Billion
≈ $10.86 Million
+22.27%
2021-03-31 Rs821.26 Million
≈ $8.88 Million
+20531525.00%
2020-03-31 Rs4.00K
≈ $43.26
-94.65%
2019-03-31 Rs74.78K
≈ $808.72
-35.80%
2018-03-31 Rs116.48K
≈ $1.26K
+1064.80%
2017-03-31 Rs10.00K
≈ $108.15
--

About Vineet Laboratories Limited

NSE:VINEETLAB India Chemicals
Market Cap
$7.69 Million
Rs711.40 Million INR
Market Cap Rank
#27546 Global
#1536 in India
Share Price
Rs37.04
Change (1 day)
-0.11%
52-Week Range
Rs29.01 - Rs45.65
All Time High
Rs117.46
About

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more